Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

This review discusses treatment strategies for alopecia areata and emphasizes the importance of primary care physicians recognizing and managing the condition, with referrals to dermatologists for more severe cases.

This study reported that dithranol treatment up to 3% concentration led to hair regrowth in alopecia areata patients who had previously failed ultra-potent steroids, with regrowth observed across all severity levels.

This study found that patients with alopecia areata had higher systemic inflammation markers compared to healthy controls, and these markers were associated with a greater risk of severe disease.

This study outlines treatment options for alopecia, suggesting intralesional corticosteroids for localized adult cases and Janus Kinase inhibitors for severe cases, emphasizing a balance between hair regrowth rate and managing side effects.

This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.

In this study, traditional treatment for pediatric alopecia areata was highly effective, with all patients achieving full hair regrowth. Tofacitinib and microneedling were less effective but are viable options for severe cases, while adverse effects were mild across all treatments.

In this study, individuals with alopecia areata in the UK incurred significant costs for managing their condition, with those experiencing more severe symptoms and lower disposable income facing higher financial burdens.

This study found that patients with alopecia areata experience reduced quality of life, particularly among women and those with severe or long-lasting disease.

In this study, Brazilian dermatologists reported that patients with alopecia areata, particularly those with severe scalp hair loss, often experience an unmet need for advanced therapies that could improve treatment outcomes beyond the limitations of current options.

This review reports that Janus kinase inhibitors and regenerative therapies, such as exosomes and platelet-rich plasma, significantly improve scalp hair regrowth in moderate-to-severe alopecia areata, though challenges like high relapse rates and socioeconomic barriers remain, underscoring the need for personalized treatment protocols.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This study found that individuals with alopecia areata have higher levels of anxiety and depression compared to healthy individuals, with longer disease duration linked to increased anxiety and severe severity predicting higher depression.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This study analyzed data from 2083 patients with alopecia areata in Europe and found that those with atopic, autoimmune, or psychiatric comorbidities encountered more severe disease and were more likely to require advanced treatments compared to those without comorbid conditions.

This review discusses the complex pathogenesis and clinical presentation of Alopecia Areata, highlighting emerging therapies that may offer hope for severe cases but reports no new results.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

In this study, researchers analyzed dermatologists' treatment practices for alopecia areata across five European countries, finding that topical and intralesional corticosteroids are most commonly prescribed for mild to moderate cases, while severe cases often see increased use of immunosuppressants and wigs.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

This study found that individuals with alopecia areata in the UK, particularly women and those of Asian ethnicity with lower income and severe symptoms, spent a significant portion of their disposable income on managing the condition, highlighting wigs and private dermatology services as primary expenses.

The researchers reviewed multiple studies and found that baricitinib, a JAK inhibitor, generally improved the condition of patients with severe alopecia areata, with minimal side effects.

This study found that JAK1 and JAK2 inhibitors increase β-catenin activity in human hair follicle cells, suggesting an additional therapeutic mechanism for treating severe alopecia areata.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

In this study, the MPV/PC ratio was identified as a potential tool for assessing disease activity in alopecia areata, with higher ratios in active and severe cases compared to inactive and mild/moderate ones.

In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.

This case study reports significant improvement in severe atopic dermatitis and alopecia areata symptoms in a patient treated with dupilumab, highlighting the potential for patient selection in optimizing therapeutic outcomes.